Stories that are getting the most attention from our readers this month.
A multicenter phase 3 randomized controlled trial enrolled 420 patients with advanced melanoma who had progressed after prior checkpoint inhibitor therapy, randomly assigning them to receive either the novel bispecific T-cell engager antibody targeting PD-1 and LAG-3 or standard chemotherapy. Responses were evaluated using RECIST criteria, with primary endpoints including objective response rate and progression-free survival. The antibody group achieved a 65% objective response rate, with many responses lasting over 12 months, significantly outperforming chemotherapy. This positions the treatment as a potential second-line option, reducing reliance on toxic chemotherapies and improving outcomes for refractory patients. Published in Nature Medicine on March 7, 2026.
The U.S. FDA has approved the first-ever gene therapy for spinal muscular atrophy (SMA) Type 1, a rare genetic muscle-wasting disease affecting infants. Developed by Novartis, the one-time intravenous treatment Zolgensma targets the root genetic cause, potentially halting progression in children under 6 months. Priced at $2.1 million per dose, it's expected to be covered by most U.S. insurers, marking a milestone in personalized medicine.
Johnson & Johnson Consumer Health issued a voluntary recall of approximately 1.5 million bottles of Neutrogena Ultra Sheer and Aveeno Protect + Refresh sunscreen sprays after independent testing detected elevated levels of benzene, a known carcinogen, in some aerosol products. The recall affects sprays manufactured between November 2023 and February 2026, sold nationwide at retailers like Walmart, Target, and CVS. No illnesses have been reported, but consumers are urged to stop using and return products for refunds; lot numbers are listed on the FDA website.
We use cookies to analyze site traffic and improve your experience. By clicking Accept, you consent to our use of analytics cookies. Privacy Policy
